Tomasz Skorski - Publications

Affiliations: 
Microbiology and Immunology Temple University, Philadelphia, PA, United States 
Area:
Molecular Biology, Immunology

182 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Calbert ML, Chandramouly G, Adams CM, Saez-Ayala M, Kent T, Tyagi M, Ayyadevara VSSA, Wang Y, Krais JJ, Gordon J, Atkins J, Toma MM, Betzi S, Boghossian AS, Rees MG, ... ... Skorski T, et al. 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular Cancer Therapeutics. PMID 38064712 DOI: 10.1158/1535-7163.MCT-23-0487  0.355
2023 Liu ZS, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphapphaiboon W, ... ... Skorski T, et al. R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts. Cancer Research. PMID 37967363 DOI: 10.1158/0008-5472.CAN-23-3239  0.319
2023 Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T. Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. Journal of Personalized Medicine. 13. PMID 37763083 DOI: 10.3390/jpm13091315  0.328
2023 Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jaśniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyż M, Skorski T, Śliwiński T. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. Genes. 14. PMID 37372475 DOI: 10.3390/genes14061295  0.326
2023 Sullivan-Reed K, Toma MM, Drzewiecka M, Nieborowska-Skorska M, Nejati R, Karami A, Wasik MA, Sliwinski T, Skorski T. Simultaneous targeting of DNA polymerase theta and PARP1 or RAD52 triggers dual synthetic lethality in homologous recombination-deficient leukemia cells. Molecular Cancer Research : McR. PMID 37358557 DOI: 10.1158/1541-7786.MCR-22-1035  0.507
2023 Wolczyk M, Serwa R, Kominek A, Klejman A, Milek J, Chwałek M, Turos-Korgul L, Charzyńska A, Dabrowski M, Dziembowska M, Skorski T, Piwocka K, Podszywalow-Bartnicka P. TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment. Iscience. 26: 106543. PMID 37123244 DOI: 10.1016/j.isci.2023.106543  0.315
2023 Li H, Chatla S, Liu X, Vekariya U, Kim D, Walt M, Lian Z, Morton G, Feng Z, Yang D, Liu H, Reed K, Childers W, Yu X, Madzo J, ... ... Skorski T, et al. Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. Research Square. PMID 37066268 DOI: 10.21203/rs.3.rs-2688694/v1  0.398
2023 Golovine K, Abalakov G, Lian Z, Chatla S, Karami A, Chitrala KN, Madzo J, Nieborowska-Skorska M, Huang J, Skorski T. ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer Journal. 13: 42. PMID 36959186 DOI: 10.1038/s41408-023-00810-0  0.551
2022 Barszczewska-Pietraszek G, Drzewiecka M, Czarny P, Skorski T, Śliwiński T. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. International Journal of Molecular Sciences. 24. PMID 36613762 DOI: 10.3390/ijms24010319  0.331
2022 Vekariya U, Toma MM, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, ... ... Skorski T, et al. DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage. Blood. PMID 36580665 DOI: 10.1182/blood.2022018428  0.516
2022 Drzewiecka M, Barszczewska-Pietraszek G, Czarny P, Skorski T, Śliwiński T. Synthetic Lethality Targeting Polθ. Genes. 13. PMID 35741863 DOI: 10.3390/genes13061101  0.409
2021 Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, ... ... Skorski T, et al. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Research. PMID 34215619 DOI: 10.1158/0008-5472.CAN-20-3761  0.446
2021 Głowacki S, Synowiec E, Szwed M, Toma M, Skorski T, Śliwiński T. Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells. Biomolecules. 11. PMID 33924068 DOI: 10.3390/biom11040610  0.433
2021 Chandramouly G, Liao S, Rusanov T, Borisonnik N, Calbert ML, Kent T, Sullivan-Reed K, Vekariya U, Kashkina E, Skorski T, Yan H, Pomerantz RT. Polθ promotes the repair of 5'-DNA-protein crosslinks by microhomology-mediated end-joining. Cell Reports. 34: 108820. PMID 33691100 DOI: 10.1016/j.celrep.2021.108820  0.376
2020 Hewlett E, Toma M, Sullivan-Reed K, Gordo J, Sliwinski T, Tulin A, Childers WE, Skorski T. Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. Medicinal Chemistry Research : An International Journal For Rapid Communications On Design and Mechanisms of Action of Biologically Active Agents. 29: 962-978. PMID 33071527 DOI: 10.1007/S00044-020-02537-0  0.381
2020 Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, ... ... Skorski T, et al. TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Reports. 33: 108221. PMID 33027668 DOI: 10.1016/j.celrep.2020.108221  0.394
2019 Nieborowska-Skorska M, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Skorski T. Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. Blood Advances. 3: 4050-4054. PMID 31816060 DOI: 10.1182/Bloodadvances.2019000756  0.51
2019 Kirschner M, Bornemann A, Schubert C, Gezer D, Kricheldorf K, Isfort S, Brümmendorf TH, Schemionek M, Chatain N, Skorski T, Koschmieder S. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms. Annals of Hematology. PMID 31748924 DOI: 10.1007/S00277-019-03836-2  0.459
2019 Toma M, Sullivan-Reed K, Śliwiński T, Skorski T. RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies. Cancers. 11. PMID 31615159 DOI: 10.3390/Cancers11101561  0.503
2019 Flis S, Bratek E, Chojnacki T, Piskorek M, Skorski T. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells. Cancers. 11. PMID 31614827 DOI: 10.1182/Blood-2019-129093  0.517
2019 Black SJ, Ozdemir AY, Kashkina E, Kent T, Rusanov T, Ristic D, Shin Y, Suma A, Hoang T, Chandramouly G, Siddique LA, Borisonnik N, Sullivan-Reed K, Mallon JS, Skorski T, et al. Molecular basis of microhomology-mediated end-joining by purified full-length Polθ. Nature Communications. 10: 4423. PMID 31562312 DOI: 10.1038/S41467-019-12272-9  0.41
2019 Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz A, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical Pharmacology. PMID 30880062 DOI: 10.1016/J.Bcp.2019.03.021  0.387
2019 Machnicki MM, Pepek M, Solarska I, Niesiobedzka-Krezel J, Seferynska I, Gora Tybor J, Zawada M, Sacha T, Sawicki W, Wasilewska E, Pruszczyk K, Rydzanicz M, Ploski R, Skorski T, Stoklosa T. ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia Blood. 134: 4148-4148. DOI: 10.1182/Blood-2019-129834  0.367
2019 Chroscicki P, Tybuchowska A, Swatler J, Samsel R, Cichocki A, Podszywalow-Bartnicka P, Roszkowska-Purska K, Tenderenda M, Smiertka W, Nieborowska-Skorska M, Skorski T, Piwocka K. Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in pancreatic cancers Annals of Oncology. 30: vii18. DOI: 10.1093/Annonc/Mdz413.063  0.502
2018 Piwocka K, Podszywałow-Bartnicka P, Skorski T. BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters. Postepy Biochemii. 64: 141-147. PMID 30656896 DOI: 10.18388/Pb.2018_124  0.441
2018 Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska-Skorska M, Radek M, Kolasa P, Matlawska-Wasowska K, Sliwinski T, Skorski T. Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent. Oncotarget. 9: 36867-36877. PMID 30627327 DOI: 10.18632/Oncotarget.26409  0.542
2018 Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leukemia & Lymphoma. 1-4. PMID 30277116 DOI: 10.1080/10428194.2018.1520988  0.384
2018 Podszywalow-Bartnicka P, Maifrede S, Le BV, Nieborowska-Skorska M, Piwocka K, Skorski T. PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions. Leukemia & Lymphoma. 1-3. PMID 29932782 DOI: 10.1182/Blood-2018-99-115041  0.543
2018 Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, ... ... Skorski T, et al. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Reports. 23: 3127-3136. PMID 29898385 DOI: 10.1016/J.Celrep.2018.05.034  0.808
2018 Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, ... ... Skorski T, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. PMID 29784639 DOI: 10.1182/Blood-2018-02-834895  0.854
2018 Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I. Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget. 9: 10585-10605. PMID 29535829 DOI: 10.18632/Oncotarget.24291  0.46
2018 Toma M, Skorski T, Sliwinski T. DNA double strand break repair - related synthetic lethality. Current Medicinal Chemistry. PMID 29421999 DOI: 10.2174/0929867325666180201114306  0.486
2017 Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Advances. 1: 1467-1472. PMID 29296788 DOI: 10.1182/Bloodadvances.2017006247  0.336
2017 Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Froehling S, Balachandran S, Skorski T, et al. PKC epsilon is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29127121 DOI: 10.1158/1078-0432.Ccr-17-2684  0.408
2017 Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T. Drugging DNA repair to target T-ALL cells. Leukemia & Lymphoma. 1-4. PMID 29115896 DOI: 10.1080/10428194.2017.1397662  0.787
2017 Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, ... ... Skorski T, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. PMID 29042365 DOI: 10.1182/Blood-2017-05-784942  0.84
2017 Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan K, Langer SK, Nejadi R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, ... Skorski T, et al. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors. Molecular Cancer Research : McR. PMID 28634224 DOI: 10.1158/1541-7786.Mcr-16-0468  0.832
2017 Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, ... ... Skorski T, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. The Journal of Clinical Investigation. PMID 28481221 DOI: 10.1172/Jci90825  0.844
2017 Mukherjee K, Sha X, Magimaidas A, Maifrede S, Skorski T, Bhatia R, Hoffman B, Liebermann DA. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia. Oncotarget. PMID 28086219 DOI: 10.18632/Oncotarget.14580  0.455
2016 Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Skorski T, Białas AJ, Sakowicz T, Kowalczyk T, Radek M, Wysokińska H, Śliwiński T. Transformed Root Extract of Leonurus sibiricus Induces Apoptosis through Intrinsic and Extrinsic Pathways in Various Grades of Human Glioma Cells. Pathology Oncology Research : Por. PMID 28032310 DOI: 10.1007/S12253-016-0170-6  0.348
2016 Zhou C, Martinez E, Di Marcantonio D, Patel-Solanki N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. PMID 27840425 DOI: 10.1038/Leu.2016.329  0.404
2016 Podszywalow-Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska-Skorska M, Koromilas AE, Skorski T, Piwocka K. Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes. Oncotarget. PMID 27802179 DOI: 10.18632/Oncotarget.12941  0.478
2016 Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. PMID 27705909 DOI: 10.18632/Oncotarget.12270  0.522
2016 Skała E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokińska H, Śliwiński T. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. The Journal of Pharmacy and Pharmacology. PMID 27696406 DOI: 10.1111/Jphp.12619  0.358
2016 Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Research. PMID 26873923 DOI: 10.1093/Nar/Gkw087  0.475
2016 Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, ... ... Skorski T, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. PMID 26864341 DOI: 10.1182/Blood-2015-11-681171  0.84
2016 Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. Plos One. 11: e0147230. PMID 26784987 DOI: 10.1371/Journal.Pone.0147230  0.394
2016 Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T. Mitochondrial mutagenesis in BCR-ABL1-expressing cells sensitive and resistant to imatinib. Acta Biochimica Polonica. PMID 26757169 DOI: 10.18388/Abp.2015_1189  0.549
2016 Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Nieborowska-Skorska M, Kolasa M, Skorski T, Wysokińska H, Śliwiński T. A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 26743778 DOI: 10.1007/S13277-015-4714-2  0.381
2016 Maifrede S, Martin K, Podszywalow-Bartnicka P, Katherine S, Langer S, Nejati R, Dasgupta Y, Gritsyuk D, Nieborowska-Skorska M, Lupey L, Piwocka K, Wasik MA, Tempera I, Skorski T. IGH/MYC Translocation in Burkitt Lymphoma Is Associated with BRCA2 Deficiency and Synthetic Lethality By PARP1 Inhibitors Blood. 128: 4111-4111. DOI: 10.1182/Blood.V128.22.4111.4111  0.829
2015 Synowiec E, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T, Blasiak J. Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib. Biomed Research International. 2015: 673512. PMID 26618175 DOI: 10.1155/2015/673512  0.462
2015 Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chemistry & Biology. 22: 1491-504. PMID 26548611 DOI: 10.1016/J.Chembiol.2015.10.003  0.429
2015 Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T. Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib. Bioresearch Open Access. 4: 334-42. PMID 26309809 DOI: 10.1089/Biores.2015.0022  0.502
2015 Synowiec E, Hoser G, Wojcik K, Pawlowska E, Skorski T, Błasiak J. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib. International Journal of Molecular Sciences. 16: 18111-28. PMID 26251899 DOI: 10.3390/Ijms160818111  0.542
2015 Sullivan K, Bolton-Gillespie E, Nieborowska-Skorska M, Cerny-Reiterer S, Valent P, Muschen M, Pomerantz R, Mazin A, Skorski T. Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors Blood. 126: 50-50. DOI: 10.1182/Blood.V126.23.50.50  0.621
2015 Sullivan K, Cramer-Morales K, McElroy DL, Ostrov D, Haas K, Nieborowska-Skorska M, Childers W, Mazin A, Hromas RA, Pomerantz R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 to Induce Synthetic Lethality in BRCA-Deficient Leukemias Blood. 126: 4434-4434. DOI: 10.1182/Blood.V126.23.4434.4434  0.565
2014 Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell Cycle (Georgetown, Tex.). 13: 3727-41. PMID 25483082 DOI: 10.4161/15384101.2014.965013  0.803
2014 Toma M, Skorski T, Sliwiński T. [Synthetic lethality as a functional tool in basic research and in anticancer therapy]. PostȩPy Higieny I Medycyny DośWiadczalnej (Online). 68: 1091-103. PMID 25228518 DOI: 10.5604/17322693.1119792  0.358
2014 Nieborowska-Skorska M, Flis S, Skorski T. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells. Leukemia. 28: 2416-8. PMID 25151958 DOI: 10.1038/Leu.2014.249  0.427
2014 Nieborowska-Skorska M, Sullivan K, Podszywalow-Bartnicka P, Hoser G, Bolton-Gillespie E, Cramer-Morales K, Slupianek A, Zhou C, Cerny-Reiterer S, Stoklosa T, Sykes SM, Valent P, Civin CI, Muschen M, Minden MD, ... ... Skorski T, et al. Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells Blood. 124: 480-480. DOI: 10.1182/Blood.V124.21.480.480  0.587
2014 Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 Protein in BCR-ABL1–positive Cells Depends on Tiar-Mediated Repression of BRCA1 mRNA Translation Blood. 124: 3129-3129. DOI: 10.1182/Blood.V124.21.3129.3129  0.804
2014 Nieborowska-Skorska M, Flis S, Skorski T. Chronic Myeloid Leukemia Stem Cells (LSCs) and Leukemia Progenitor Cells (LPCs) Display Overlapping and Unique Mechanisms of Genomic Instability: The Role of PI3k-AKT and PI3k-Rac2-PAK Pathways Blood. 124: 1791-1791. DOI: 10.1182/Blood.V124.21.1791.1791  0.639
2013 Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, ... ... Skorski T, et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 122: 1293-304. PMID 23836560 DOI: 10.1182/Blood-2013-05-501072  0.54
2013 Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia. 27: 2253-4. PMID 23604228 DOI: 10.1038/Leu.2013.123  0.387
2013 Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, ... ... Skorski T, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 121: 4175-83. PMID 23543457 DOI: 10.1182/Blood-2012-11-466938  0.605
2013 Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leukemia & Lymphoma. 54: 1151-8. PMID 23121619 DOI: 10.3109/10428194.2012.745524  0.397
2013 Mukherjee K, Sha X, Skorski T, Bhatia R, Hoffman B, Liebermann D. GADD45a Is a Tumor Suppressor in BCR-ABL-Driven Leukemogenesis Blood. 122: 1467-1467. DOI: 10.1182/Blood.V124.21.4530.4530  0.539
2013 Nieborowska-Skorska M, Slupianek A, Hoser G, Bolton-Gillespie E, Tulin A, Cerny-Reiterer S, Valent P, Muschen M, Sykes SM, Skorski T. Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells Blood. 122: 810-810. DOI: 10.1182/Blood.V122.21.810.810  0.646
2013 Dasgupta Y, Koptyra M, Nieborowska-Skorska M, Gillespie EB, Stoklosa T, Hoser G, Wasik M, Muschen M, Richardson C, Skorski T. Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias Blood. 122: 1466-1466. DOI: 10.1182/Blood.V122.21.1466.1466  0.661
2012 Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia. 27: 629-34. PMID 23047475 DOI: 10.1038/Leu.2012.294  0.613
2012 Flis K, Irvine D, Copland M, Bhatia R, Skorski T. Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia & Lymphoma. 53: 2474-8. PMID 22616753 DOI: 10.3109/10428194.2012.696313  0.466
2012 Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, ... ... Skorski T, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 119: 4253-63. PMID 22411871 DOI: 10.1182/Blood-2011-10-385658  0.831
2012 Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation. Current Hematologic Malignancy Reports. 7: 87-93. PMID 22328017 DOI: 10.1007/S11899-012-0114-5  0.484
2012 Falinski R, Nieborowska-Skorska M, Skorski T. BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks. Leukemia Research. 36: 241-4. PMID 22036635 DOI: 10.1016/J.Leukres.2011.10.007  0.492
2012 Bolton E, Schemionek M, Klein H, Hoser G, Flis S, Lange T, Kerstiens L, Nieborowska-Skorska M, Müller MC, Modi H, Bhatia R, Koschmieder S, Skorski T. Genomic Instability in CML-CP originates From the Most Primitive Imatinib-Refractory Leukemia Stem Cells Blood. 120: 909-909. DOI: 10.1182/Blood.V120.21.909.909  0.845
2012 Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 Kinase Inhibits DNA Glycosylases to Enhance Oxidative DNA Damage and Stimulate Genomic Instability Blood. 120: 520-520. DOI: 10.1182/Blood.V120.21.520.520  0.613
2012 Cramer K, Nieborowska-Skorska M, Slupianek A, Sliwinski T, Irvine D, Copland M, Skorski T. RAD52-Dependent Synthetic Lethality Eradicates Leukemia Stem Cells Blood. 120: 3-3. DOI: 10.1182/Blood.V120.21.3.3  0.652
2011 Skorski T. BCR-ABL1 kinase: hunting an elusive target with new weapons. Chemistry & Biology. 18: 1352-3. PMID 22118668 DOI: 10.1016/J.Chembiol.2011.11.001  0.463
2011 Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. American Journal of Hematology. 86: 811-9. PMID 21850662 DOI: 10.1002/Ajh.22097  0.386
2011 Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, Skorski T. Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. Cancer Research. 71: 5381-6. PMID 21693657 DOI: 10.1158/0008-5472.Can-11-0068  0.843
2011 Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 118: 1062-8. PMID 21653319 DOI: 10.1182/Blood-2010-09-307256  0.851
2011 Koptyra M, Stoklosa T, Hoser G, Glodkowska-Mrowka E, Seferynska I, Klejman A, Blasiak J, Skorski T. Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis. Leukemia. 25: 1259-67. PMID 21519342 DOI: 10.1038/Leu.2011.91  0.629
2011 Skorski T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leukemia & Lymphoma. 52: 23-9. PMID 21299457 DOI: 10.3109/10428194.2010.546912  0.546
2011 Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, Nowicki MO, Blasiak J, Skorski T. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Research. 71: 842-51. PMID 21123451 DOI: 10.1158/0008-5472.Can-10-1066  0.608
2011 Cramer K, Bolton E, Nieborowska-Skorska M, Flis S, Skorski T. Targeting DNA Repair Gene, RAD52, Induces Exhaustion of the Proliferating CML-CP Leukemia Stem Cells Carrying Oxidative DNA Damage Blood. 118: 447-447. DOI: 10.1182/Blood.V118.21.447.447  0.85
2011 Bolton E, Schemionek M, Klein H, Kerstiens L, Koschmieder S, Skorski T. Genomic Instability Originates From Leukemia Stem Cells in a Mouse Model of CML-CP Blood. 118: 445-445. DOI: 10.1182/Blood.V118.21.445.445  0.836
2011 Nieborowska-Skorska M, Kopinski P, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Ambrozek M, Seferynska I, Niesiobedzka-Krezel J, Bolton E, ... ... Skorski T, et al. Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells Blood. 118: 2736-2736. DOI: 10.1182/Blood.V118.21.2736.2736  0.836
2010 Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. The Journal of Clinical Investigation. 120: 2254-64. PMID 20592475 DOI: 10.1172/Jci41246  0.456
2010 Dasgupta Y, Virgili A, Koptyra M, Nacheva EP, Skorski T. Sensitivity to Imatinib In BCR-ABL1-Positive Chronic Myeloid Leukemia Cells Depends on the Presence of Normal ABL1. Blood. 116: 3405-3405. DOI: 10.1182/Blood.V116.21.3405.3405  0.84
2010 Kopinski P, Nieborowska-Skorska M, Hoser G, Ngaba D, Ray R, Koptyra M, Bolton E, Seferynska I, Stoklosa T, Slupianek A, Reddy MR, Sattler M, Skorski T. Mitochondrial Respiratory Chain Complex III Causes Genomic Instability In CML-CP. Blood. 116: 1211-1211. DOI: 10.1182/Blood.V116.21.1211.1211  0.833
2010 Bolton E, Kamp L, Modi H, Bhatia R, Koschmieder S, Skorski T. CML-CP Mouse Model of Genomic Instability. Blood. 116: 1210-1210. DOI: 10.1182/Blood.V116.21.1210.1210  0.832
2010 Slupianek A, Dasgupta Y, Ren S, Cramer K, Skorski T. Targeting Phosphotyrosine-315 In RAD51 Recombinase to Prevent BCR-ABL1 - Mediated Unfaithful Homeologous Recombination Repair. Blood. 116: 1190-1190. DOI: 10.1182/Blood.V116.21.1190.1190  0.861
2009 Slupianek A, Jozwiakowski SK, Gurdek E, Skorski T. BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B. Leukemia. 23: 2308-10. PMID 19657362 DOI: 10.1038/Leu.2009.164  0.415
2009 Slupianek A, Dasgupta Y, Ren S, Cramer K, Skorski T. Targeting BCR/ABL-RAD51 Interaction to Prevent Unfaithful Homeologous Recombination Repair. Blood. 114: 3272-3272. DOI: 10.1182/Blood.V114.22.3272.3272  0.851
2009 Nieborowska-Skorska M, Koptyra M, Bolton E, Ray R, Ngaba D, Hoser G, Stoklosa T, Slupianek A, Kopinski P, Skorski T. ROS-Induced DNA Damage Causing Genomic Instability in CML Stem and/or Progenitor Cells and in Quiescent and/or Proliferating Cells: Role of Mitochondrial Respiratory Chain Complex III. Blood. 114: 3268-3268. DOI: 10.1182/Blood.V114.22.3268.3268  0.833
2009 Stoklosa T, Koptyra M, Hoser G, Seferynska I, Glodkowska E, Skorski T. BCR/ABL Requires Fanconi Anemia D2 (FANCD2) Protein to Transform Hematopoetic Stem Cells. Blood. 114: 3249-3249. DOI: 10.1182/Blood.V114.22.3249.3249  0.657
2008 Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ, Aulitzky W, Skorski T. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Research. 68: 6884-8. PMID 18757400 DOI: 10.1158/0008-5472.Can-08-1101  0.624
2008 Sliwinski T, Czechowska A, Szemraj J, Morawiec Z, Skorski T, Blasiak J. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutation Research. 654: 162-7. PMID 18602021 DOI: 10.1016/J.Mrgentox.2008.06.002  0.588
2008 Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Research. 68: 2576-80. PMID 18413724 DOI: 10.1158/0008-5472.Can-07-6858  0.543
2008 Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia. 22: 1969-72. PMID 18401418 DOI: 10.1038/Leu.2008.78  0.33
2008 Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leukemia & Lymphoma. 49: 610-4. PMID 18398719 DOI: 10.1080/03093640701859089  0.646
2008 Koptyra M, Stoklosa T, Hoser G, Seferynska I, Glodkowska E, Skorski T. Monoubiquitination of the Fanconi Anemia D2 (FANCD2) Protein Regulates the Transforming Potential of BCR/ABL Blood. 112: 3189-3189. DOI: 10.1182/Blood.V112.11.3189.3189  0.649
2008 Slupianek A, Ren S, Skorski T. Selective Anti-Leukemia Targeting of the Interaction Between BCR/ABL and Mammalian RecA Homologs Blood. 112: 195-195. DOI: 10.1182/Blood.V112.11.195.195  0.665
2008 Nieborowska-Skorska M, Koptyra M, Hoser G, Ray R, Ngaba D, Bolton E, Skorski T. Mechanisms Generating free Radicals in CML Stem/Progenitor Cell Populations Causing DNA Damage and Genomic Instability Blood. 112: 192-192. DOI: 10.1182/Blood.V112.11.192.192  0.837
2007 Skorski T. Genomic instability: The cause and effect of BCR/ABL tyrosine kinase. Current Hematologic Malignancy Reports. 2: 69-74. PMID 20425353 DOI: 10.1007/S11899-007-0010-6  0.635
2007 Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 21: 1347-52. PMID 17495971 DOI: 10.1038/Sj.Leu.2404733  0.306
2007 Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood. 110: 651-60. PMID 17431132 DOI: 10.1182/Blood-2006-08-042630  0.828
2007 Cramer K, Penserga ET, Reddy A, Wosen J, Skorski T. BCR/ABL and Other Oncogenic Fusion Tyrosine Kinases (FTKs) Stimulate Single Strand Annealing (SSA), the Rare and Extremely Unfaithful DNA Double-Strand Break Repair Pathway To Facilitate Genomic Instability in Hematologic Malignancies. Blood. 110: 998-998. DOI: 10.1182/Blood.V110.11.998.998  0.597
2007 Nieborowska-Skorska M, Slupianek A, Stoklosa T, Poplawski T, Cramer K, Skorski T. BCR/ABL Kinase Elevates ROS-Mediated Oxidative DNA Damage in CML Stem/Progenitor Cells and Affects the Efficiency and Fidelity of DNA Repair To Induce Genetic Instability. Blood. 110: 34-34. DOI: 10.1182/Blood.V110.11.34.34  0.621
2007 Stoklosa T, Poplawski T, Basak G, Slupianek A, Blasiak J, Seferynska I, Skorski T. BCR/ABL Kinase Inhibits Mismatch Repair To Reduce Apoptosis and Induce Point Mutations. Blood. 110: 32-32. DOI: 10.1182/Blood.V110.11.32.32  0.63
2007 Slupianek A, Jozwiakowski S, Pytel D, Poplawski T, Nowicki M, Skorski T. BCR/ABL Stimulates WRN Helicase Activity To Facilitate DNA Double-Strand Breaks Repair. Blood. 110: 1024-1024. DOI: 10.1182/Blood.V110.11.1024.1024  0.618
2006 Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene. 26: 11-20. PMID 16785987 DOI: 10.1038/Sj.Onc.1209756  0.609
2006 Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 5: 994-1000. PMID 16687921 DOI: 10.4161/Cc.5.9.2722  0.846
2006 Nieborowska-Skorska M, Hoser G, Rink L, Malecki M, Kossev P, Wasik MA, Skorski T. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Research. 66: 4108-16. PMID 16618731 DOI: 10.1158/0008-5472.Can-05-1584  0.778
2006 Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 108: 319-27. PMID 16527898 DOI: 10.1182/Blood-2005-07-2815  0.502
2006 Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutation Research. 603: 74-82. PMID 16388976 DOI: 10.1182/Blood.V106.11.1525.1525  0.62
2006 Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. Dna Repair. 5: 243-50. PMID 16297667 DOI: 10.1016/J.Dnarep.2005.10.005  0.585
2006 Trojanek J, Croul S, Ho T, Wang JY, Darbinyan A, Nowicki M, Del Valle L, Skorski T, Khalili K, Reiss K. T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. Journal of Cellular Physiology. 206: 35-46. PMID 15965906 DOI: 10.1002/Jcp.20425  0.4
2006 Hartman AD, Wilson-Weekes A, Cripe LD, Bennett B, Friedman G, Worland P, Druker B, Ren S, Skorski T, Boswell HS. In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2. Blood. 108: 584-584. DOI: 10.1182/Blood.V108.11.584.584  0.489
2006 Bargaoanu M, Skorski T. Mutations in the BCR/ABL Kinase Encoding the Resistance to Imatinib Mesylate Do Not Modify the Sensitivity to Genotoxic Treatment. Blood. 108: 2194-2194. DOI: 10.1182/Blood.V108.11.2194.2194  0.56
2006 Rink L, Stoklosa T, Nieborowska-Skorska M, Slupianek A, Seferynska I, Skorski T. Enhanced Phosphorylation of Nbs1, a Member of DNA Repair/Checkpoint Complex RAD50-Mre11-Nbs1, Can Be Targeted Simultaneously with BCR/ABL Kinase To Eliminate Leukemia Cells. Blood. 108: 2127-2127. DOI: 10.1182/Blood.V108.11.2127.2127  0.854
2006 Koptyra M, Skorski T. Fanconi Anemia D2 (FANCD2) Is Required To Overcome Reactive Oxygen Species (ROS) - Induced DNA Double-Strand Breaks in BCR/ABL-Positive Leukemias. Blood. 108: 2119-2119. DOI: 10.1182/Blood.V108.11.2119.2119  0.623
2005 Ren SY, Xue F, Feng J, Skorski T. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Experimental Hematology. 33: 1222-8. PMID 16219545 DOI: 10.1016/J.Exphem.2005.06.030  0.514
2005 Ren SY, Bolton E, Mohi MG, Morrione A, Neel BG, Skorski T. Phosphatidylinositol 3-kinase p85α subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: Molecular mechanisms and biological consequences Molecular and Cellular Biology. 25: 8001-8008. PMID 16135792 DOI: 10.1128/Mcb.25.18.8001-8008.2005  0.798
2005 Wang JY, Ho T, Trojanek J, Chintapalli J, Grabacka M, Stoklosa T, Garcia FU, Skorski T, Reiss K. Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence. Oncogene. 24: 3748-58. PMID 15782124 DOI: 10.1038/Sj.Onc.1208537  0.512
2005 Slupianek A, Gurdek E, Koptyra M, Nowicki MO, Siddiqui KM, Groden J, Skorski T. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin. Oncogene. 24: 3914-22. PMID 15750625 DOI: 10.1038/Sj.Onc.1208545  0.609
2005 Nieborowska M, Stoklosa T, Datta M, Czechowska A, Rink L, Blasiak J, Skorski T. ATR-Chk1 Axis Is Activated, but the Function of Chk1 Is Disrupted in BCR/ABL Leukemia Cells Responding to DNA Damage. Blood. 106: 2883-2883. DOI: 10.1182/Blood.V106.11.2883.2883  0.85
2005 Koptyra M, Houghtaling S, Grompe M, Skorski T. Fanconi Anemia D2 Protein Contributes to BCR/ABL-Mediated Transformation of Hematopoietic Cells. Blood. 106: 2878-2878. DOI: 10.1182/blood.V106.11.2878.2878  0.566
2005 Slupianek A, Jozwiakowski S, Gurdek E, Nowicki MO, Skorski T. BCR/ABL Regulates the Expression and Interacts with Werner Syndrome Helicase/Exonuclease To Modulate Its Biochemical Properties. Blood. 106: 2873-2873. DOI: 10.1182/Blood.V106.11.2873.2873  0.592
2005 Stoklosa T, Slupianek A, Basak G, Skorski T. BCR/ABL Kinase Disrupts Formation of Mismatch Repair Complex To Induce Genomic Instability. Blood. 106: 2864-2864. DOI: 10.1182/Blood.V106.11.2864.2864  0.575
2005 Slupianek A, Nowicki MO, Skorski T. BCR/ABL Modifies the Kinetics and Fidelity of DNA Double-Strand Breaks Repair in Leukemia Cells. Blood. 106: 1982-1982. DOI: 10.1182/Blood.V106.11.1982.1982  0.629
2004 Slupianek A, Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Experimental Hematology. 32: 1265-71. PMID 15588951 DOI: 10.1016/J.Exphem.2004.11.002  0.472
2004 Stoklosa T, Slupianek A, Datta M, Nieborowska-Skorska M, Nowicki MO, Koptyra M, Skorski T. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle (Georgetown, Tex.). 3: 1463-72. PMID 15492510 DOI: 10.4161/Cc.3.11.1229  0.522
2004 Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 104: 3746-53. PMID 15304390 DOI: 10.1182/Blood-2004-05-1941  0.593
2004 Majsterek I, Slupianek A, Hoser G, Skórski T, Blasiak J. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Biochimie. 86: 53-65. PMID 14987801 DOI: 10.1016/J.Biochi.2003.10.008  0.547
2004 Chipitsyna G, Slonina D, Siddiqui K, Peruzzi F, Skorski T, Reiss K, Sawaya BE, Khalili K, Amini S. HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression. Oncogene. 23: 2664-71. PMID 14755242 DOI: 10.1038/Sj.Onc.1207417  0.553
2004 Koptyra M, Falinski R, Nowicki MO, Blasiak J, Skorski T. BCR/ABL Oncogenic Kinase Stimulates DNA Oxidative Damage To Induce Self-Mutagenesis Causing Resistance to Imatinib Mesylate. Blood. 104: 714-714. DOI: 10.1182/Blood.V104.11.714.714  0.56
2004 Ren S, Xue F, Feng J, Skorski T. Intrinsic Regulation of the Interactions between the SH3 Domain of p85 Subunit of Phosphatidylinositol-3 Kinase and BCR/ABL Oncogenic Tyrosine Kinase. Blood. 104: 2961-2961. DOI: 10.1182/Blood.V104.11.2961.2961  0.442
2004 Nieborowska-Skorska M, Hoser G, Malecki M, Wasik M, Skorski T. BCR/ABL→STAT5 Pathway Stimulates Helix-Loop-Helix Id-1 Protein To Enhance the MMP9 - Dependent Invasiveness of Leukemia Cells. Blood. 104: 2954-2954. DOI: 10.1182/Blood.V104.11.2954.2954  0.525
2004 Ren S, Bolton E, Skorski T. Phosphatidylinositol 3-Kinase p85 Subunit-Dependent Interaction with BCR/ABL: Molecular Mechanism and Biological Consequences. Blood. 104: 2953-2953. DOI: 10.1182/Blood.V104.11.2953.2953  0.797
2003 Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, Peruzzi F, Khalili K, Skorski T, Reiss K. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Molecular and Cellular Biology. 23: 7510-24. PMID 14559999 DOI: 10.1128/Mcb.23.21.7510-7524.2003  0.353
2003 Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS, Lautier D, Skorski T. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood. 102: 2632-7. PMID 12829601 DOI: 10.1182/Blood-2002-10-3207  0.557
2003 Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene. 22: 3952-63. PMID 12813469 DOI: 10.1038/Sj.Onc.1206620  0.441
2003 Blasiak J, Gloc E, Drzewoski J, Wozniak K, Zadrozny M, Skórski T, Pertynski T. Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutation Research. 535: 25-34. PMID 12547280 DOI: 10.1016/S1383-5718(02)00289-9  0.523
2003 Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leukemia Research. 27: 267-73. PMID 12537980 DOI: 10.1016/S0145-2126(02)00163-7  0.596
2002 Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene. 21: 8591-604. PMID 12476306 DOI: 10.1038/Sj.Onc.1206087  0.425
2002 Błasiak J, Gloc E, Młynarski W, Drzewoski J, Skórski T. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leukemia Research. 26: 1093-6. PMID 12443881 DOI: 10.1016/S0145-2126(02)00051-6  0.565
2002 Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. The Embo Journal. 21: 5766-74. PMID 12411494 DOI: 10.1093/Emboj/Cdf562  0.502
2002 Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 21: 5868-76. PMID 12185586 DOI: 10.1038/Sj.Onc.1205724  0.546
2002 Gloc E, Warszawski M, Młynarski W, Stolarska M, Hoser G, Skorski T, Błasiak J. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Acta Biochimica Polonica. 49: 121-8. PMID 12136932  0.423
2002 Błasiak J, Gloc E, Woźniak K, Młynarski W, Stolarska M, Skórski T, Majsterek I. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chemico-Biological Interactions. 140: 1-18. PMID 12044557 DOI: 10.1016/S0009-2797(02)00012-1  0.472
2002 Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Reviews. Cancer. 2: 351-60. PMID 12044011 DOI: 10.1038/Nrc799  0.522
2002 Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 99: 4531-9. PMID 12036885 DOI: 10.1182/Blood.V99.12.4531  0.451
2002 Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Molecular and Cellular Biology. 22: 4189-201. PMID 12024032 DOI: 10.1128/Mcb.22.12.4189-4201.2002  0.508
2002 Majsterek I, Blasiak J, Mlynarski W, Hoser G, Skórski T. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biology International. 26: 363-70. PMID 11991666 DOI: 10.1006/Cbir.2002.0865  0.58
2002 Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Journal of Immunology (Baltimore, Md. : 1950). 168: 466-74. PMID 11751994 DOI: 10.4049/Jimmunol.168.1.466  0.529
2001 Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance Molecular Cell. 8: 795-806. PMID 11684015 DOI: 10.1016/S1097-2765(01)00357-4  0.578
2001 Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1 Oncogene. 20: 4640-4649. PMID 11498787 DOI: 10.1038/Sj.Onc.1204625  0.336
2000 Nieborowska-Skorska M, Slupianek A, Skorski T. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells. Oncogene. 19: 4117-24. PMID 10962572 DOI: 10.1038/Sj.Onc.1203754  0.474
1999 Putney SD, Brown J, Cucco C, Lee R, Skorski T, Leonetti C, Geiser T, Calabretta B, Zupi G, Zon G. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense & Nucleic Acid Drug Development. 9: 451-8. PMID 10555152 DOI: 10.1089/Oli.1.1999.9.451  0.311
1999 Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. The Journal of Experimental Medicine. 189: 1229-42. PMID 10209040 DOI: 10.1084/Jem.189.8.1229  0.501
1999 Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 96: 3092-7. PMID 10077642 DOI: 10.1073/Pnas.96.6.3092  0.401
1998 Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M, Wasik M, Calabretta B. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac Proceedings of the National Academy of Sciences of the United States of America. 95: 11858-11862. PMID 9751755 DOI: 10.1073/Pnas.95.20.11858  0.538
1998 Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, Grassilli E, Lozzo RV, Cooper DR, Calabretta B. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. The Embo Journal. 17: 4442-55. PMID 9687511 DOI: 10.1093/Emboj/17.15.4442  0.505
1998 Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, Calabretta B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. The Journal of Experimental Medicine. 187: 1995-2007. PMID 9625759 DOI: 10.1084/Jem.187.12.1995  0.413
1998 Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B. The SH3 Domain Contributes to BCR/ABL-Dependent Leukemogenesis In Vivo: Role in Adhesion, Invasion, and Homing Blood. 91: 406-418. DOI: 10.1182/Blood.V91.2.406.406_406_418  0.505
1997 Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway Embo Journal. 16: 6151-6161. PMID 9321394 DOI: 10.1093/Emboj/16.20.6151  0.399
1997 Calabretta B, Skorski T. Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Critical Reviews in Eukaryotic Gene Expression. 7: 117-24. PMID 9034718 DOI: 10.1615/Critreveukargeneexpr.V7.I1-2.70  0.418
1997 Calabretta B, Skorski T. BCR/ABL regulation of PI-3 kinase activity. Leukemia & Lymphoma. 23: 473-6. PMID 9031078 DOI: 10.3109/10428199609054856  0.423
1997 Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. Journal of the National Cancer Institute. 89: 124-33. PMID 8998181 DOI: 10.1093/Jnci/89.2.124  0.372
1997 Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV. Ectopic expression of decorin protein core causes generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases Matrix Biology. 16: 121. DOI: 10.1016/S0945-053X(97)90047-0  0.383
1996 Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 93: 13137-42. PMID 8917557 DOI: 10.1073/Pnas.93.23.13137  0.351
1996 Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. The Journal of Experimental Medicine. 182: 1645-53. PMID 7500009 DOI: 10.1084/Jem.182.6.1645  0.342
1996 Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo R, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice Blood. 88: 1005-1012. DOI: 10.1182/Blood.V88.3.1005.1005  0.352
1995 Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 92: 7016-20. PMID 7624361 DOI: 10.1073/Pnas.92.15.7016  0.408
1995 Perrotti D, Melotti P, Skorski T, Casella I, Peschle C, Calabretta B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Molecular and Cellular Biology. 15: 6075-87. PMID 7565760 DOI: 10.1128/Mcb.15.11.6075  0.316
1995 Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Wen S, Zon G, Gewirtz A, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood. 86: 726-736. DOI: 10.1182/Blood.V86.2.726.Bloodjournal862726  0.433
1994 Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. The Journal of Experimental Medicine. 179: 1855-65. PMID 8195713 DOI: 10.1084/Jem.179.6.1855  0.463
1994 Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the United States of America. 91: 4504-8. PMID 8183938 DOI: 10.1073/Pnas.91.10.4504  0.315
1993 Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. The Journal of Clinical Investigation. 92: 194-202. PMID 8325984 DOI: 10.1172/Jci116549  0.387
1993 Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Szczylik C, Zon G, Arlinghaus RB, Gewirtz A, Perussia B, Calabretta B. p120 GAP requirement in normal and malignant human hematopoiesis Journal of Experimental Medicine. 178: 1923-1933. PMID 8245773 DOI: 10.1084/Jem.178.6.1923  0.393
1991 Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (New York, N.Y.). 253: 562-5. PMID 1857987 DOI: 10.1126/Science.1857987  0.409
Show low-probability matches.